Form 4: Travere Therapeutics CFO Sells Shares to Cover Tax Obligations

Christopher R. Cline, CFO of Travere Therapeutics, sold 54 shares of common stock on April 11, 2024, to cover tax withholding obligations related to vested restricted stock units.

Summary

• On April 11, 2024, Christopher R. Cline, the Chief Financial Officer of Travere Therapeutics, sold 54 shares of the company's common stock.
• The sale was executed at a price of $6.74 per share.
• This transaction was conducted to cover the tax withholding obligations associated with the settlement of vested restricted stock units.
• The sale was mandated by Travere Therapeutics' equity incentive plans, requiring Cline to fund the tax obligation through a 'sell to cover' transaction.
• Following the transaction, Cline directly owns 70,849 shares of Travere Therapeutics stock.

Sentiment

Score: 5

Explanation: This is a neutral event. The sale is related to tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This particular filing reflects a standard 'sell to cover' transaction, which is a common practice among executives receiving equity compensation.

Key Dates